RT Journal Article
SR Electronic
T1 Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.120.252791
DO 10.2967/jnumed.120.252791
A1 caroline bodet-milin
A1 Alain faivre-chauvet
A1 Thomas Carlier
A1 Catherine Ansquer
A1 Aurore Rauscher
A1 Eric Frampas
A1 frederique Toulgoat
A1 Damien Masson
A1 Mickael Bourgeois
A1 Evelyne Cerato
A1 Vincent Rohmer
A1 Olivier Couturier
A1 delphine Drui
A1 David M Goldenberg
A1 Robert M Sharkey
A1 Jacques Barbet
A1 Francoise Kraeber-Bodere
YR 2021
UL http://jnm.snmjournals.org/content/early/2021/02/05/jnumed.120.252791.abstract
AB Introduction: Pretargeting parameters for use the anti-CEA (carcinoembryonic antigen) bispecific monoclonal antibody TF2 and the 68Ga-labeled IMP288 peptide (68Ga-IMP288) for Immuno-PET have been optimized in a first-in-human study performed in MTC (medullary thyroid carcinoma (MTC) patients (iPET-MTC study). The aim of this post-hoc analysis was to determine the sensitivity of Immuno-PET in relapsing MTC patients, in comparison with conventional imaging and 18F-DOPA PET/CT (DOPA-PET/CT). Methods: Twenty-five studies were analyzed in 22 patients. All patients received Immuno-PET 1-h and 2-h after 68Ga-IMP288 injection pretargeted by TF2, in addition to neck-thoracic-abdominal-pelvic computed tomography (CT), bone and liver magnetic resonance imaging (MRI), and DOPA-PET/CT. Gold standard (GS) was histology and/or confirmation by one other imaging method and/or imaging follow-up. Results: 190 lesions were confirmed by the GS: 89 in lymph nodes, 14 in lungs, 46 in liver, 37 in bone, and 4 in other sites (subcutaneous, heart, brain, and pancreas). 210 abnormal foci were detected by Immuno-PET. Among these, 174 (83%) were confirmed as true-positive by the GS. Immuno-PET showed a higher overall sensitivity (92%) than DOPA-PET/CT (65%). Regarding metastatic sites, Immuno-PET had a higher sensitivity than CT, DOPA-PET/CT or MRI for lymph nodes (98% vs 83% for CT and 70% for DOPA-PET/CT), liver (98% vs 87% for CT, 65% DOPA-PET/CT, and 89% for MRI) and bone (92% vs 64% for DOPA-PET/CT and 86% for MRI), whereas sensitivity was lower for lung metastases (29% vs 100% for CT and 14% for DOPA-PET/CT). Tumor SUVmax at 60 min ranged from 1.2 to 59.0 with intra- and inter-patient variability. Conclusion: This post-hoc study demonstrates that anti-CEA immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than DOPA-PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination.